{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:43:02Z","timestamp":1773924182792,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ministry of Health & Welfare, Republic of Korea","award":["HC15C1056"],"award-info":[{"award-number":["HC15C1056"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","strokejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2017.02.022","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T23:15:39Z","timestamp":1492038939000},"page":"1383-1390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation"],"prefix":"10.1016","volume":"26","author":[{"given":"Yun Kyung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Ji","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rae Woong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyeong-Moon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Sang","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Youn","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oh Young","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1212\/01.wnl.0000250340.05202.8b","article-title":"The increasing incidence of anticoagulant-associated intracerebral hemorrhage","volume":"68","author":"Flaherty","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0015","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","article-title":"Bleeding complications of oral anticoagulant treatment: aninception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy","volume":"348","author":"Palareti","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.tips.2009.05.001","article-title":"Genetic and clinical factors relating to warfarin dosing","volume":"30","author":"Jonas","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0030","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","article-title":"A pharmacogenetic versus a clinical algorithm for warfarin dosing","volume":"369","author":"Kimmel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0035","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","article-title":"A randomized trial of genotype-guided dosing of warfarin","volume":"369","author":"Pirmohamed","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0040","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAME-TT(2)R(2) score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0045","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/archinte.167.3.229","article-title":"The influence of patient adherence on anticoagulation control with warfarin: results from the international normalized ratio adherence and genetics (in-range) study","volume":"167","author":"Kimmel","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0050","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0055","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-121-9-199411010-00009","article-title":"Interactions of warfarin with drugs and food","volume":"121","author":"Wells","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0060","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/ajhp\/57.13.1221","article-title":"Potential interactions between alternative therapies and warfarin","volume":"57","author":"Heck","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5853\/jos.2015.17.2.192","article-title":"Lack of association of clinical factors (SAME-TT2R2) with CYP2C9\/VKORC1 genotype and anticoagulation control quality","volume":"17","author":"Park","year":"2015","journal-title":"J Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0070","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0075","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the atria (anticoagulation and risk factors in atrial fibrillation) study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0080","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0085","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2217\/14622416.8.4.329","article-title":"Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients","volume":"8","author":"Cho","year":"2007","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0090","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.clinthera.2011.09.004","article-title":"Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation","volume":"33","author":"Cho","year":"2011","journal-title":"Clin Ther"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0100","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0105","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0110","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1160\/TH08-08-0499","article-title":"How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database","volume":"101","author":"Rietbrock","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.21456","article-title":"Admission international normalized ratio and acute infarct volume in ischemic stroke","volume":"64","author":"Ay","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0120","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0125","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2217\/pgs.10.49","article-title":"Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups","volume":"11","author":"Scott","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2125.2005.02448.x","article-title":"Allele and genotype frequencies of CYP2C9 in a Korean population","volume":"60","author":"Bae","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0135","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2217\/14622416.9.2.169","article-title":"Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations","volume":"9","author":"Wu","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0140","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa0708078","article-title":"Genetic determinants of response to warfarin during initial anticoagulation","volume":"358","author":"Schwarz","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0145","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7326\/0003-4819-155-10-201111150-00003","article-title":"Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial","volume":"155","author":"Schulman","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0150","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1016\/j.jacc.2010.03.009","article-title":"Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study)","volume":"55","author":"Epstein","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0155","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0160","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1160\/TH14-10-0859","article-title":"Safety and efficacy of well managed warfarin. A report from the Swedish quality register auricula","volume":"113","author":"Sjogren","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0165","doi-asserted-by":"crossref","first-page":"e44064","DOI":"10.1371\/journal.pone.0044064","article-title":"Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis","volume":"7","author":"Jorgensen","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0170","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0175","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1161\/STROKEAHA.108.523159","article-title":"Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?","volume":"39","author":"Eckman","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2017.02.022_bib0180","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5853\/jos.2016.00052","article-title":"Asian patients with stroke plus atrial fibrillation and the dose of non-vitamin k oral anticoagulants","volume":"18","author":"Bang","year":"2016","journal-title":"J Stroke"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717300708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305717300708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T06:39:39Z","timestamp":1760942379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305717300708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S1052305717300708"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2017.02.022","relation":{},"ISSN":["1052-3057"],"issn-type":[{"value":"1052-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of Stroke and Cerebrovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2017.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Stroke Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}